TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07570654: Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Sponsor: COMPASS Pathways · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 300 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$3,928,888

Rescue Site Savings

+$2,592,256

Unlock Full NCT07570654 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07570654 Rescue Dossier →